SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D illustration of tow GLP-1 therapy autoinjectors
IPO
Metsera Moves Fast in Crowded Obesity Market With IPO Plans
Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight loss in a Phase IIa study.
January 13, 2025
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
Mergers & acquisitions
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
January 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
 · 
5 min read
 · 
Kate Goodwin
Staying ahead of your competitors. Accelerated development of the company. Innovation vision. Customized solution. Unique skills. Red paper plane and whites. 3d render
FDA
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming particularly in the oncology and neurosciences spaces.
January 13, 2025
 · 
7 min read
 · 
Heather McKenzie
Blue DNA molecule helix with red human heart. Hereditary heart diseases, diagnosis of genetic diseases concept. Gene editing, biotechnology engineering. Low poly style Wireframe light structure Vector
Gene therapy
5 Cardio Gene Therapies on the Near Horizon
Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic for cardiovascular diseases including congestive heart failure, chronic refractory angina and cardiomyopathy.
January 13, 2025
 · 
9 min read
 · 
Tristan Manalac
Business
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)
In this short teaser, BioSpace’s Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder of the Emily Whitehead Foundation about anticipated discussions at the upcoming GenScript Biotech Forum.
January 10, 2025
 · 
1 min read
 · 
Lori Ellis
cutting off a row of people into pieces
Layoffs
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.
January 10, 2025
 · 
1 min read
 · 
Angela Gabriel
Vector design of a human heart with flat color and multiple colors line heart shapes. Square composition.
Series A
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
January 10, 2025
 · 
2 min read
 · 
Heather McKenzie
Poster. Contemporary art collage. Blue and yellow hands peeking out of black holes in space to make a deal. Abstract vibrant artwork. Concept of pop art, positive emotions. Minimal art design.
Venture capitalists
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
January 10, 2025
 · 
1 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS